Skip to content

Evaluating the Effectiveness of the Nurse-led Mindfulness-Based Group Program

Nurse-led Mindfulness-Based Group Program Incorporating Psychoeducation About Rumination for Clients With Mental Disorders Presenting Depressive Symptoms: A Prospective Multicenter Controlled Trial in Clinical Daycare Settings - Nurse-led Mindfulness-Based Group Program Incorporating Psychoeducation About Rumination for Clients With Mental Disorders Presenting Depressive Symptoms: A Prospective Multicenter Controlled Trial in Clinical Daycare Settings

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000042859
Enrollment
50
Registered
2021-03-15
Start date
2020-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Those with a psychiatrist&#39

Interventions

A participant takes part in the program (60 minutes each session, for a total of 8 sessions) and performs homework (the breathing method) every day in addition to receiving usual care. usual care alon

Sponsors

Kobe-Tokiwa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (a) having a primary diagnosis of mental disorders (codes F00-F99) listed in the International Classification of Diseases, 10th Revision (ICD-10) (b) having at least mild severity of depressive symptoms based on a Quick Inventory of Depressive Symptomatology (QIDS) total score >= 6 (c) answering "yes" to the question "Have you ever experienced rumination (dwelling on past failures or unpleasant events)?" (d) being at least 20 years old

Exclusion criteria

Exclusion criteria: (a) already engaging in daily mindfulness training (b) currently undergoing structured psychotherapy (e.g., cognitive behavioral therapy) (c) having a diagnosis of dementia, intellectual disability (moderate or above), or being at high risk of self-harm or harm to others (d) being unable to obtain permission from a primary psychiatrist to participate in the study (e) taking a high-level dose of antipsychotic medications (chlorpromazine equivalent of >= 1000 mg/d) (f) having extremely severe depressive symptoms (QIDS score of >= 21)

Design outcomes

Primary

MeasureTime frame
Rumination, Drop out

Secondary

MeasureTime frame
Cognitive Bias, Depression Symptoms, Adverse Events, The Level of Engagement with the Program

Countries

Japan

Contacts

Public ContactMiki Eguchi

Kobe-Tokiwa University Department of Nursing, Faculty of Health Science

m-eguchi@kobe-tokiwa.ac.jp078-611-1821

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026